← All indications
Retinitis Pigmentosa
Hereditary, progressive degeneration of the retina due to death of ROD PHOTORECEPTORS initially and subsequent death of CONE PHOTORECEPTORS. It is characterized by deposition of pigment in the retina.
Subtype terms (4)
More specific conditions that are subtypes of Retinitis Pigmentosa in the MeSH hierarchy.
- Alstrom Syndrome
2 drugs (1 approved, 1 experimental)
- Bardet-Biedl Syndrome
2 drugs approved
- Kearns-Sayre Syndrome
- Usher Syndromes
7 drugs (1 approved, 6 experimental)
Drugs by status
Phase 3 trials (15)
Phase 2 trials (42)
- brimonidine
- valproic acid
- hydroxychloroquine
- hrpc
- levodopa
- carbidopa
- ushstat
- aav-rpgr
- alga dunaliella bardawill
- allogeneic adipose derived mesenchymal stem cell
- human embryonic stem cell derived retinal pigmented epithelial cells
- human retinal progenitor cells
- lycium barbarum
- rst-001
- methotrexate
- aflibercept
- sildenafil
- exosomes from mesenchymal stem cells
- cenegermin-bkbj
- fish oil
- revakinagene taroretcel
- cpk850
- gs030-dp
- autologous hematopoietic stem cells
- aav2/5-hpde6b
- raav2tyf-grk1-rpgr
- rep/cap-deleted, recombinant adeno-associated virus vector expressing an enhanced light-sensitive channelrhodopsin gene
- qr-1123
- 4d-125
- raav.hpde6a
- +12 more
Phase 1 trials (17)
Other trials (3)
Organizations
Organization Involved with Phase 3 Indications (5)
Organization Involved with Phase 2 Indications (52)
- Sanofi
- Novartis
- Allergan
- Applied Genetic Technologies Corp
- Bayer
- DSM
- Neurotech Pharmaceuticals
- NightstaRx Limited
- ProQR Therapeutics
- RetroSense Therapeutics
- jCyte, Inc
- GenSight Biologics
- ReNeuron Limited
- Stem Cells Arabia
- The EMMES Corporation
- Retina Foundation of the Southwest
- National Center for Complementary and Integrative Health (NCCIH)
- Beirut Eye Specialist Hospital
- University of London
- Gadjah Mada University
- Ophthalmic Consultants of Boston
- Retina-Vitreous Associates Medical Group
- Seoul National University
- STZ eyetrial
- The Hong Kong Polytechnic University
- University of Michigan
- Columbia University
- Tel Aviv University
- University of California, Irvine
- University of California, San Francisco
- +22 more
Organization Involved with Phase 1 Indications (17)
- Novelion Therapeutics
- Centocor
- Red de Terapia Celular
- Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
- Cedars-Sinai Medical Center
- Johns Hopkins University
- Spanish National Health System
- Universidad de Murcia
- Capital Medical University
- University of California, Davis
- Southern Medical University
- Hebrew University
- Pomeranian Medical University
- Public Health Service, Murcia
- Guangzhou Jeeyor Medical Research Co.,Ltd.
- Chinese Academy of Medical Sciences
- Eyecure Therapeutics Inc.
Organization Involved with Other Experimental Indications (1)